齐拉西酮与利培酮对精神分裂症阴性症状及认知功能的影响
Controlled study of ziprasidone and risperidone effect in negative symptom and cognitive impairment in schizophrenia
徐健 1黄嘉艺2
作者信息
- 1. 511457 广州市南沙中心医院精神科
- 2. 528333 广东佛山市顺德区伍仲珮纪念医院
- 折叠
摘要
目的：探讨齐拉西酮、利培酮对精神分裂症阴性症状和认知功能的影响。方法选取2013年1—9月佛山市顺德区伍仲佩纪念医院住院部所收治的75例精神分裂症患者为研究对象，随机分为齐拉西酮组（n＝39）和利培酮组（n＝36），分别给予齐拉西酮和利培酮治疗8周。采用精神病阴性与阳性症状量表（ PANSS）、韦氏记忆量表（ WMS）、威斯康星卡片分类测验（ WCST）分别于治疗前及治疗8周后对两组进行评定。结果治疗8周后，齐拉西酮组与利培酮组总体疗效无显著差异（P＞0．05），齐拉西酮组精神病阴性症状量表、韦氏记忆测验、威斯康星卡分类测验多项成绩优于治疗前和利培酮组（ P＜0．05）。结论齐拉西酮比利培酮更有助于阴性症状和认知功能的改善。
Abstract
Objective To explore the efficacy of ziprasidone and risperidone for improving negative symptom and cognitive function in schizophrenia.Methods In this study, we enrolled 75 schizophrenia patients in our hospital from January 2013 to September 2013.These patients were divided into ziprasidone group ( n=39) and risperidone group ( n =36 ) .Positive and Negative Symptom Scale ( PANSS ) , Wechsler Memory Scale ( WMS) , Wisconsin Card Sorting Test ( WCST) were employed to assess negative symptom and cognitive function before and after treatment respectively for 8 weeks.Results After treatment for 8 weeks, there were nosignificant differences on overall effect between the two groups ( P>0.05) and all the results of PANSS, WMS and WCST in ziprasidone group were significantly better than before treatment and risperidone group (P<0.05). Conclusions Compared with risperidone, ziprasidone can remarkable improve the negative symptom and cognitive function in patients with schizophrenia.
关键词
齐拉西酮/利培酮/精神分裂症/阴性症状/认知功能Key words
Ziprasidone/Risperidone/Schizophrenia/Negative symptoms/Cognitive function引用本文复制引用
出版年
2015
NETL
NSTL
维普
万方数据